ATE285239T1 - Dna enthaltende impfstoffen - Google Patents

Dna enthaltende impfstoffen

Info

Publication number
ATE285239T1
ATE285239T1 AT97923435T AT97923435T ATE285239T1 AT E285239 T1 ATE285239 T1 AT E285239T1 AT 97923435 T AT97923435 T AT 97923435T AT 97923435 T AT97923435 T AT 97923435T AT E285239 T1 ATE285239 T1 AT E285239T1
Authority
AT
Austria
Prior art keywords
nucleic acid
formulations
products
containing dna
vaccines containing
Prior art date
Application number
AT97923435T
Other languages
English (en)
Inventor
David B Volkin
Robert K Evans
Mark Bruner
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9610192.8A external-priority patent/GB9610192D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of ATE285239T1 publication Critical patent/ATE285239T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97923435T 1996-04-26 1997-04-22 Dna enthaltende impfstoffen ATE285239T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1704996P 1996-04-26 1996-04-26
GBGB9610192.8A GB9610192D0 (en) 1996-05-15 1996-05-15 DNA vaccine formulations
US84452597A 1997-04-18 1997-04-18
PCT/US1997/006655 WO1997040839A1 (en) 1996-04-26 1997-04-22 Dna vaccine formulations

Publications (1)

Publication Number Publication Date
ATE285239T1 true ATE285239T1 (de) 2005-01-15

Family

ID=27268281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97923435T ATE285239T1 (de) 1996-04-26 1997-04-22 Dna enthaltende impfstoffen

Country Status (8)

Country Link
EP (1) EP0906110B1 (de)
JP (1) JP4386965B2 (de)
AT (1) ATE285239T1 (de)
AU (1) AU727306B2 (de)
CA (1) CA2252565C (de)
DE (1) DE69732029T2 (de)
ES (1) ES2234018T3 (de)
WO (1) WO1997040839A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387695B1 (en) 1997-12-23 2002-05-14 Merck & Co., Inc. DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof
PT1061955E (pt) * 1998-03-13 2005-08-31 Wyeth Corp Composicao de polinucleotido, metodo de preparacao e sua utilizacao
US7276359B1 (en) 1998-03-13 2007-10-02 Wyeth Polynucleotide composition, method of preparation, and use thereof
EP1555033A3 (de) * 1998-03-13 2005-08-17 Wyeth Polynukleotidzusammensetzung, Verfahren zu deren Herstellung und Verwendung
US6818626B1 (en) * 1998-07-17 2004-11-16 Mirus Corporation Chelating systems for use in the delivery of compounds to cells
JP2001316297A (ja) * 2000-02-23 2001-11-13 Kaken Pharmaceut Co Ltd 遺伝子包埋リポソーム製剤及びその製法
US20020041884A1 (en) * 2000-03-07 2002-04-11 Evans Robert K. Adenovirus formulations
MXPA04005942A (es) 2001-12-20 2005-05-16 Schering Corp Composiciones y metodos de sintaxina 3.
WO2003061629A2 (en) * 2002-01-25 2003-07-31 Glaxo Group Limited Dna dosage forms
GB0201736D0 (en) * 2002-01-25 2002-03-13 Glaxo Group Ltd DNA dosage forms
AU2003218168A1 (en) * 2002-03-15 2003-09-29 University Of Southern California Ophthalmic solutions for delivery of expression vectors
KR101152561B1 (ko) 2002-09-27 2012-06-01 파우더젝트 리서치 리미티드 핵산 코팅된 입자
GB2395950A (en) * 2002-12-06 2004-06-09 Hong Kong Dna Chips Ltd A method for extracting, purifying and preserving genetic material
US7381422B2 (en) 2002-12-23 2008-06-03 Vical Incorporated Method for producing sterile polynucleotide based medicaments
AU2003293195A1 (en) * 2002-12-23 2004-07-29 Vical Incorporated Method for freeze-drying nucleic acid/block copolymer/cationic surfactant complexes
CA2708716A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccines for malaria
US20180036409A1 (en) * 2014-12-29 2018-02-08 Bonac Corporation Composition containing nucleic acid molecule stably

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
CA2115061A1 (en) * 1991-08-06 1993-02-18 David S. Sigman Method of isolation of dna
AU691114B2 (en) * 1995-06-07 1998-05-07 Whatman Plc Dry solid medium for storage and analysis of genetic material
US5811406A (en) * 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes

Also Published As

Publication number Publication date
EP0906110B1 (de) 2004-12-22
JP2002504085A (ja) 2002-02-05
AU727306B2 (en) 2000-12-07
DE69732029D1 (de) 2005-01-27
ES2234018T3 (es) 2005-06-16
WO1997040839A1 (en) 1997-11-06
AU2924297A (en) 1997-11-19
JP4386965B2 (ja) 2009-12-16
CA2252565A1 (en) 1997-11-06
EP0906110A1 (de) 1999-04-07
CA2252565C (en) 2010-11-23
DE69732029T2 (de) 2006-02-23

Similar Documents

Publication Publication Date Title
ATE285239T1 (de) Dna enthaltende impfstoffen
YU40701A (sh) Piperidini kao modulatori ccr5
HUP0402259A2 (hu) Vakcinák
MX9700229A (es) Vacuna de polinucleotido para virus de papiloma.
NO20001768L (no) Viruskapsomervaksine, fremgangsmÕte til fremstilling samt anvendelse derav
ME00513B (me) Azabicikloalkani kao modulatori ccr5
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
DE69738581D1 (de) Menschliche dnase i hyperaktive varianten
PT851927E (pt) Compostos para imunoterapia e diagnostico de tuberculose
HUP0203056A1 (hu) Vakcinakészítmény
DE69929310D1 (de) Tumorassoziierte antigenderivate der mage-familie, nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
PT1487485E (pt) Adjuvantes de imidazoquinolina para vacinas de adn
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
ES2151506T3 (es) Moleculas de adn recombinante que codifican enzimas aminopeptidasa y su uso en la preparacion de vacunas contra infecciones por helmintos.
DK1025237T3 (da) Human kontrolpunktskinase, hCDS1, præparater og fremgangsmåder
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
FR2744455B1 (fr) Nouvelles sequences d'acides nucleiques de la famille des facteurs suppresseurs de tumeurs, produits d'expression correspondants et leurs applications
MY101874A (en) Vaccine
AU2002223402A1 (en) A novel gene therapy agent for haemophilia b and its preparation method
WO2000065063A3 (en) Nucleic acid vaccines against rickettsial diseases and methods of use
IL131436A0 (en) Compositions for treatment of disorders involving programmed cell death
HUP9800247A2 (hu) Humán endoglin gén promóter és annak alkalmazása

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties